Compare PFLT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFLT | ABCL |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | PFLT | ABCL |
|---|---|---|
| Price | $9.26 | $3.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $10.75 | $7.75 |
| AVG Volume (30 Days) | 880.3K | ★ 3.0M |
| Earning Date | 02-09-2026 | 11-06-2025 |
| Dividend Yield | ★ 13.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $261,427,000.00 | $35,325,000.00 |
| Revenue This Year | $11.66 | $25.45 |
| Revenue Next Year | N/A | $10.07 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | ★ 40.28 | 7.17 |
| 52 Week Low | $8.40 | $1.89 |
| 52 Week High | $11.50 | $6.52 |
| Indicator | PFLT | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 40.39 |
| Support Level | $9.01 | $3.32 |
| Resistance Level | $9.14 | $3.82 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 42.28 | 27.78 |
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.